Tan M, Heizmann C W, Guan K, Schafer B W, Sun Y
Department of Molecular Biology, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105, USA.
FEBS Lett. 1999 Feb 26;445(2-3):265-8. doi: 10.1016/s0014-5793(99)00135-0.
S100A2, a calcium binding protein of the EF-hand family, was recently identified to be inducible by etoposide, a p53 activator. A potential p53 binding site was identified in the promoter of the S100A2 gene, which binds to purified p53 as well as p53 in nuclear extract activated by etoposide. Transactivation assays using the promoter driven luciferase reporters revealed that the S100A2 promoter was transcriptionally activated by wild-type p53, but not by p53 mutants, in a dose-dependent as well as a p53 binding site-dependent manner. The p53-induced transactivation of the S100A2 promoter was enhanced by etoposide and blocked by a dominant negative p53 mutant. Furthermore, endogenous S100A2 mRNA expression is induced by etoposide in p53 positive, but not in p53 negative cells. Thus, p53 appears to positively regulate S100A2 expression.
S100A2是一种EF手型家族的钙结合蛋白,最近被确定可被拓扑替康(一种p53激活剂)诱导。在S100A2基因的启动子中鉴定出一个潜在的p53结合位点,该位点可与纯化的p53以及经拓扑替康激活的核提取物中的p53结合。使用启动子驱动的荧光素酶报告基因进行的反式激活分析表明,S100A2启动子可被野生型p53转录激活,但不能被p53突变体激活,且呈剂量依赖性以及p53结合位点依赖性。拓扑替康可增强p53诱导的S100A2启动子反式激活,而显性负性p53突变体则可阻断这种激活。此外,拓扑替康可在p53阳性细胞中诱导内源性S100A2 mRNA表达,但在p53阴性细胞中则不能。因此,p53似乎正向调节S100A2的表达。